| Autor: |
Ruiz, Nazaret Gamez, Morales, Rodrigo, Gutierrez, Antonia, Moreno‐Gonzalez, Ines |
| Zdroj: |
Alzheimer's & Dementia: The Journal of the Alzheimer's Association; Dec2021 Supplement S9, Vol. 17, p1-1, 1p |
| Abstrakt: |
Background: Current treatments for Alzheimer´s disease (AD) only ameliorate the symptoms, but none of them delays or halts disease progression. In recent years, stem cells have received growing attention as a potential therapy for brain disorders. Patients' self‐derive stem cells offer the possibility to avoid rejection and a more personalized treatment. However, there is an urgent need to replace the conventional intracerebral stem cell therapy for a less invasive method to avoid some of the technical challenges. Our recently published results indicate that peripheral treatment with neural precursors (NPs) ameliorates clinical symptoms by reducing the disease‐associated neuroinflammation in a mouse model of Parkinson's disease. Therefore, we hypothesize that intravenous administration of NPs could be considered as a non‐invasive therapy to ameliorate memory impairment in mouse models of AD. Method: NPs derived from mesenchymal stem cells and induced pluripotent stem cells were intravenously injected into APP/PS1 and P301S mice before and after brain pathology is stablished. At the age of 7 months old, experimental and control animals were subjected learning and memory tasks and brain analyzed. Result: NP‐treated mice demonstrated a significant decreased of cognitive impairment compared to PBS‐injected animals as well as improved motor coordination in P301S mice. Histological analysis showed that although amyloidogenic deposits were slightly reduced, microglial activation decreased after the treatment. Conclusion: The preclinical analysis of NPs peripheral inoculation suggests that these cells could be considered as a potential treatment to reduce AD‐related pathology. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
